Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus
Authors
Del Vecchio, M.Atkinson, V. G.
Ryll, B.
Menzies, A. M.
Aubin, F.
Sileni, V. C.
Ferraresi, V.
Lesimple, T.
Rinaldi, G.
Saiag, P.
Robert, C.
Dutriaux, C.
Gogas, H. J.
Demidov, L.
Gupta, Avinash
Banerjee, H.
Sudhir, S.
Miranda, F.
Lau, M. R.
Grob, J. J.
Affiliation
Department Of Medical Oncology And Hematology, Unit of Melanoma Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - MilanIssue Date
2022
Metadata
Show full item recordCitation
Del Vecchio M, Atkinson VG, Ryll B, Menzies AM, Aubin F, Sileni VC, et al. Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus. Annals of Oncology. 2022 Sep;33(7):S914-S. PubMed PMID: WOS:000866211601077.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1059Additional Links
https://dx.doi.org/10.1016/annonc/annonc1059Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1059